Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy

Journal of Hepatology

Volumn 49, Issue 3, 2008, Pages 329-338

  Burton Jr , James R ^a   Klarquist, Jared ^a   Im, KyungAh ^b   Smyk Pearson, Sue ^a   Golden Mason, Lucy ^a   Castelblanco, Nicole ^a   Terrault, Norah ^c   Rosen, Hugo R ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral therapy; Hepatitis C virus; Interferon ; T cell immunity; T regulatory cells

Indexed keywords

GAMMA INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; CYTOMETRY; DRUG WITHDRAWAL; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RACE DIFFERENCE; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; TH1 CELL;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-GAMMA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TREATMENT OUTCOME;

EID: 48449093228     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.05.020     Document Type: Article

References (35)

1. Dienstag J.L., and McHutchison J.G. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 130 (2006) 231-264
2. Davis G.L., Albright J.E., Cook S.E., and Rosenberg D. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9 (2003) 331-338
3. Hadziyannis S.J., Sette H.J., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
4. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 (2001) 1395-1406
5. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in person infected with hepatitis C virus. J Exp Med 191 (2000) 1499-1512
6. Tang K.H., Herrmann E., Cooksley H., Tatman N., Chokshi S., Williams R., et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin. J Hepatol 43 (2005) 776-782
7. Barnes E., Salio M., Cerundolo V., Medlin J., Murphy S., Dusheiko G., et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother 48 (2004) 3382-3389
8. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161 (1998) 1947-1953
9. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C.M., Ikeda M., et al. Immune evasion of hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor adaptor protein TRIF. Proc Natl Acad Sci USA 102 (2005) 2992-2997
10. Foy E., Li K., Wang C., Sumpter Jr. R., Ikeda M., Lemon S.M., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 (2003) 1145-1148
11. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., and Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
12. Grotta S., Stilla A., Wack A., D'Andrea A., Nuti S., D'Oro U., et al. Inhibition of natural killer cells through the engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195 (2002) 35-42
13. + T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123 (2002) 1070-1083
14. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., and Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118 (2000) 346-355
15. Barnes E., Harcourt G., Brown D., Lucas M., Phillips R., Dusheiko G., et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36 (2002) 743-754
16. Kaplan D.E., Sugimoto K., Ikeda F., Stadanlick J., Valiga M., Shetty K., et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 41 (2005) 1365-1375
17. Pilli M., Zerbini A., Penna A., Orlandini A., Lukasiewicz E., Pawlotsky J.M., et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV Project). Gastroenterology 133 (2007) 1132-1143
18. + T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 115 (2005) 1361-1368
19. Cabrera R., Tu Z., Xu Y., Firpi R.J., Rosen H.R., Liu C., et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 (2003) 1062-1071
20. Sugimoto K., Ikeda F., Stadanlick J., Nunes N.A., Alter H.J., and Chang K.M. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38 (2003) 1437-1448
21. + T cells during chronic hepatitis C virus infection. J Virol 79 (2005) 7860-7867
22. Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afhal N., et al. Peginterferon and ribavirin treatment in African Americans and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131 (2006) 470
23. Rosen H.R., Weston S.J., Im K., Yang H., Burton Jr. J.R., Erlich H., et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 46 (2007) 350-358
24. + T cells during persistent hepatitis C virus infection. J Virol 79 (2005) 7852-7859
25. Mills K.H. Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol 4 (2004) 841-855
26. Schwartz R.H. Natural regulatory T cells and self-tolerance. Nat Rev Immunol 6 (2005) 327-330
27. + regulatory cells. J Immunol 176 (2006) 3321-3329
28. + regulatory T-cell-mediated suppression. Immunology 118 (2006) 240-249
29. Macon-Lemaitre L., and Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 115 (2005) 170-178
30. + regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004) 971-979
31. + T cells. J Immunol 178 (2007) 788-797
32. + T helper cells in chronic HCV infection. Hepatology 41 (2005) 1019-1028
33. Rehermann B., and Naoumov N.V. Immunological techniques in viral hepatitis. J Hepatol 46 (2007) 508-520
34. + T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance. J Infect Dis 195 (2007) 1315-1319
35. Rahman F., Heller T., Sobao Y., Mizukoshi E., Nascimbeni M., Alter H., et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 40 (2004) 87-97